Evidence map›Paper›PMID 42088612›Full record

ArticleCase reports in oncological medicine2026

Chylous Ascites: A Rare Initial Presentation of High-Grade Follicular Lymphoma.

Rama Nada, Ani Gvajaia, Ali Raza, Mohammed Raji

Abstract read
In one paragraph

Article in Case reports in oncological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Rama NadaDepartment of Internal Medicine, New York City Health and Hospitals Corporation (NYCHHC), Lincoln Medical and Mental Health Center, Bronx, New York, USA, nychealthandhospitals.org.ORCID https://orcid.org/0009-0001-7150-9512
Ani GvajaiaDivision of Hematology and Oncology, Henry Ford Health System, St John Hospital, Detroit, Michigan, USA, henryford.com.
Ali RazaDepartment of Surgical Oncology, New York City Health and Hospitals Corporation (NYCHHC), Lincoln Medical and Mental Health Center, Bronx, New York, USA, nychealthandhospitals.org.
Mohammed RajiDepartment of Pathology, New York City Health and Hospitals Corporation (NYCHHC), Lincoln Medical and Mental Health Center, Bronx, New York, USA, nychealthandhospitals.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chylous ascites is an uncommon condition characterized by the accumulation of triglyceride-rich, milky fluid in the peritoneal cavity due to lymphatic disruption or obstruction. Although lymphoma is a leading cause of malignant chylous ascites, its occurrence as an initial presentation remains rare. Case Presentation: A 69-year-old woman presented with a three-month history of postprandial abdominal pain, weight loss, anorexia, and dyspnea. Imaging revealed extensive abdominal and pelvic lymphadenopathy with bilateral pleural effusions. Diagnostic laparoscopy demonstrated milky peritoneal fluid, and fluid analysis confirmed chylous ascites (triglycerides, 1361 mg/dL). Lymph node biopsy demonstrated high-grade B-cell lymphoma with morphological features favoring follicular lymphoma. Immunohistochemistry revealed a markedly elevated Ki-67 proliferative index (> 90%), and genomic profiling identified pathogenic Conclusions: This case highlights chylous ascites as a rare but important presenting feature of lymphoma. Its recognition should prompt early histopathologic evaluation and multidisciplinary management. In selected postoperative or frail patients, rituximab monotherapy can serve as an effective bridge to full chemotherapy, facilitating recovery and improving outcomes. Early diagnosis and targeted treatment remain essential to prevent complications from lymphatic loss and to optimize prognosis in lymphoma-associated chylous ascites.

Indexed as

chylous ascitesfollicular lymphomalymphadenopathylymphomanon-Hodgkinpleural effusionrituximab

Identifiers

PMID42088612
PMCPMC13136516

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.